- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cipla Secure CDSCO Panel Nod To Study Rizatriptan Benzoate Orally Disintegrating Tablet
New Delhi: Granting approval to conduct bioequivalence (BE) study of Rizatriptan Benzoate Orally Disintegrating Tablets 5mg, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has recommended the drug major Cipla to reduce sampling time points and blood volume during the study.This came in wake of proposal presented by the drug major Cipla...
New Delhi: Granting approval to conduct bioequivalence (BE) study of Rizatriptan Benzoate Orally Disintegrating Tablets 5mg, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has recommended the drug major Cipla to reduce sampling time points and blood volume during the study.
Bioequivalence studies are special type of studies where two drugs or two sets of formulation of the same drug are compared to show that they have nearly equal bioavailability and pharmacokinetic/pharmacodynamic (PK/PD) parameters. The purpose of bioequivalence (BE) studies is to identify pharmaceutical equivalents or alternatives to be used interchangeably for the same therapeutic effect as a previously marketed drug.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.